Nilotinib for treating MSA: A preclinical proof of concept study
Objective: To assess the effects of nilotinib on motor behavior, α-synuclein burden and surrogate markers of neurodegeneration in a transgenic mouse model of multiple system…Accuracy of the International Parkinson Disease and Movement Disorder Society Progressive Supranuclear Palsy Diagnostic Criteria (IPD-MDS-PSP)
Objective: To evaluate the accuracy of the IPD-MDS-PSP criteria to differentiate PSP-Richardson (PSP-R) from PSP-parkinsonism (PSP-P), the most common PSP phenotypes. Background: The new International…Methylphenidate in Progressive Supranuclear Palsy [PSP] – Old drug, New Indications?
Objective: To evaluate whether Methylphenidate can improve some symptoms of PSP. Background: PSP is a neurodegenerative disorder with limited therapeutic options. Methylphenidate[MPH] , a drug…Vascular parkinsonism: Clinical features and comparison with Parkinson’s disease
Objective: To define the clinical features of vascular parkinsonism (VP) and compare it to idiopathic Parkinson’s disease (iPD). Background: The main differential diagnosis of VP…The Timed Up & Go test (time) is inversely associated with fall frequency in progressive supranuclear palsy
Objective: This study aimed to elucidate the appropriate assessments associated with fall frequency in progressive supranuclear palsy (PSP). Background: PSP is an adult-onset neurodegenerative disease,…Atypical Response to Apomorphine in a Patient with Multiple System Atrophy
Objective: Multiple system atrophy (MSA) is a sporadic neurodegenerative disease clinically characterized by cerebellar signs, parkinsonism and autonomic dysfunction. MSA is classified into two sub-types;…Effects of mannitol treatment in a mice model of multiple system atrophy (MSA)
Objective: The aim of this study was to examine the effect of mannitol treatment in a mice model of MSA. Background: Alpha-synuclein aggregation represents the…Midbrain/pons area ratio and clinical features predict the prognosis of PSP
Objective: This study aims to characterize the natural history of PSP and to find predictors of shorter survival and early institutionalization including neuroimaging biomarkers. Background:…Analysis of Tau Burden and Distribution on the Spectrum of PSP Subtypes
Objective: The aim of this study was to assess the previous hypothesis about relationship between clinical spectrum of Progressive Supranuclear Palsy (PSP) and tau burden…Amyotrophic Lateral Sclerosis-Progressive Supranuclear Palsy Phenotype with Negative C9ORF72 Mutation
Objective: We report a rare case of amyotrophic lateral sclerosis (ALS) / progressive supranuclear palsy (PSP) phenotype. Background: Increasing evidence supports a common pathophysiology between…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.